🔴 Senti Biosciences is trading 8.1% down in pre-market with no company-specific catalyst identified

Senti Biosciences is trading 8.1% lower at $0.20 in pre-market; no company-specific announcement explaining the October 22 decline was identified.

• The latest major company news was October 15 shareholder approval of the merger and a possible reverse split; this is not a fresh catalyst.
• Broader markets are sharply weaker pre-market as investors reassess AI spending after Meta and Tesla results, alongside geopolitical and oil-price concerns. This risk-off backdrop may be contributing, but a direct link to Senti Biosciences has not been established.